A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

Phase 1 Completed 31 enrolled Genentech, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh classification.

Timeline

Start: 2025-01-31
Primary completion: 2025-11-27
Completion: 2025-11-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Divarasib	Small molecule	—	Oral

Indications

No indication recorded.